Transgene and BioInvent Share Promising Clinical Insights

Transgene and BioInvent Present at ESMO 2025

Transgene, a biotech company focused on innovative virus-based immunotherapies, and BioInvent International AB, known for its groundbreaking immune-modulatory antibodies, are about to make headlines. Together, they are set to share exciting updates regarding their joint research on the armed oncolytic virus BT-001 during the prestigious European Society for Medical Oncology (ESMO) Annual Meeting.

Significant Findings on BT-001

In a collaborative presentation, both companies will unveil the translational data and updated clinical results from their Phase I study related to BT-001. This promising research highlights the potential of BT-001 combined with pembrolizumab in providing substantial benefits for patients battling advanced cancers.

Overview of the Study Results

The findings from the study indicate that the intra-tumoral injection of BT-001, when combined with pembrolizumab, shows a manageable safety profile and is well tolerated among participants. An important aspect of the results showcases the anti-tumor activity, especially among patients with melanoma and leiomyosarcoma, who experienced notable tumor shrinkage in both injected and non-injected lesions.

Encouraging Responses

Among the 13 patients who participated, the treatment demonstrated remarkably encouraging responses. A patient with PD(L)-1 resistant melanoma exhibited a partial response lasting six months, while another suffered from heavily pretreated and immune checkpoint inhibitor-naive leiomyosarcoma experienced an impressive partial response lasting 16 months. This data supports the idea that BT-001 could serve as an effective treatment option to enhance responses to immunotherapies in refractory patients.

Future Presentations and Availability

The prestigious ESMO Annual Meeting in Berlin will take place from October 17 to 21, 2025. The poster presentation regarding this research will occur on October 20. Following the conference, the poster will also be available for public viewing on Transgene's official website, allowing interested parties to access extensive information regarding this breakthrough study.

Innovations Behind BT-001

BT-001 is a product of Transgene's innovative Invir.IO® platform, engineered using a proprietary oncolytic virus model. This advanced virus has been designed not only to attack cancer cells but also to foster an immune response. Notably, it is combined with a Treg-depleting recombinant human anti-CTLA-4 antibody developed by BioInvent. This strategy signifies a cutting-edge approach to cancer treatment that may pave the way for new therapeutic options.

Co-Development and Collaboration

This exciting journey of BT-001 is a 50/50 collaboration between Transgene and BioInvent. In the Phase I stage, BT-001 has been successful both as a standalone treatment and when used in conjunction with Merck's KEYTRUDA (pembrolizumab). The positive outcomes observed in the study further emphasize the potential of BT-001 in transforming currently incurable cancers.

Study Overview

The Phase I/IIa study, categorized under NCT04725331, focuses on a multicenter, open-label, dose-escalation evaluation of BT-001, assessing it both alone and with pembrolizumab. The Phase I portion recently reached its conclusion as they successfully enrolled the last patient.

Transforming Tumors

One remarkable outcome of using BT-001 is its ability to convert 'cold' tumors into 'hot' tumors, leading to significant T-cell infiltration in the tumor microenvironment. These changes are promising indicators of enhanced immune response.

Contact Information

For further inquiries, key contacts from Transgene include Caroline Tosch, the Corporate and Scientific Communications Manager, reachable at +33 (0)3 68 33 27 38 or via email at communication@transgene.fr. Additionally, BioInvent's VP of Investor Relations, Cecilia Hofvander, can be contacted at +46 (0)46 286 85 50 or through her email at cecilia.hofvander@bioinvent.com.

Frequently Asked Questions

What is BT-001?

BT-001 is an oncolytic virus engineered for cancer treatment, utilizing a proprietary viral backbone and combining it with immune-modulatory antibodies.

What results were presented regarding BT-001?

The study showcased promising tumor responses in patients, indicating the potential of BT-001 when combined with pembrolizumab.

When will the results be shared publicly?

Results will be presented at the ESMO Annual Meeting from October 17 to 21, 2025, and will also be accessible on Transgene's website thereafter.

Who are the key companies involved?

The primary companies involved are Transgene and BioInvent, both focused on innovative cancer therapies.

How can I get in touch for more information?

Contact details for corporate communication are provided, including emails and phone numbers for representatives from both companies.

About The Author

Hello, I'm 30-year-old financial writer and expert Addison Perry, and I love to simplify the intricacies of the financial industry. I've committed myself over the years to deciphering the subtleties of investing techniques and economic trends and converting them into doable guidance that anybody can use. My goal with writings and books is to make money interesting and approachable so that readers may take charge of their financial futures.

My enthusiasm to empowerment and education has propelled me through my career in finance. I write because I think that everyone should be able to make educated financial decisions, and I try to provide that. Regardless of experience level with investing, my work is intended to provide insightful analysis and practical advice to enable you to thrive in the always changing financial environment. I appreciate you traveling with me toward success and financial literacy.

Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.